(NO-LND). We compared surgical outcomes (operative time, blood loss, need for blood transfusions) and complications within 30 days from surgery (stratified as follows: intra-operative, in-hospital, post-discharge, non-surgical).

Results Overall 109 patients were included: 71 (65.45%) and 38 (34.86%) in LND and NO-LND groups, respectively. No differences were found in terms of baseline characteristics between the groups. Surgical approach was laparoscopic in 95 patients (87.16%) and open surgery in 14 (12.84%). Median operative time was 325 min (240–390) for LND and 135 (170–200.5) for NO-LND ($p < 0.001$). No significant differences between the groups were found in terms of blood loss, transfusion rates and complications.

Conclusions The execution of systematic lymphadenectomy for aEOC was associated with prolonged operative time. However, in a referral center for minimally invasive surgery, the retroperitoneal staging did not influence the overall surgical morbidity.

IGCS20_1430

400 REAL WORLD OUTCOMES OF OLAPARIB MAINTENANCE THERAPY IN PATIENTS WITH BRCA1/2-MUTATED PLATINUM-SENSITIVE EPITHELIAL OVARIAN CANCER

¹A McLaren*, ²M White, ²D Cartwright, ¹J Brown, ¹M Randhawa, ²T Roxburgh, ¹R Glasspool. ¹Beatson West of Scotland Cancer Centre, UK; ²University of Glasgow, UK

10.1136/ijgc-2020-IGCS.346

Introduction Maintenance Olaparib is approved for use after response to platinum-based chemotherapy in both first line and relapsed BRCA-mutated ovarian cancer. Here we present real world outcomes for women treated in a single institution.

Methods Between January 2017 and November 2019, data was collected retrospectively from patients with a germline or somatic BRCA mutation who received at least one cycle of Olaparib after > 4 cycles of platinum-based chemotherapy.

Results 53 patients were included in analysis (median age 60 years; 40 relapsed, 13 first line). In relapse, 14 (35%) continue on olaparib and 20 (50%) patients had died (median follow-up 21 months, range 8–42 months). Median progression free survival (PFS) was 13 months (95%CI 8.4–17.6 months). 5 patients had a PFS of over 2 years. Median overall survival (OS) was 24 months (95%CI 21.3–26.7 months). In first line, (median follow-up 12 months, range 8–16 months), 5 patients (38%) had progressed and 2 (15%) had died.

Overall, 27 patients (53%) required dose interruption (DI), and 36 (68%) required a dose reduction (DR). The most common reasons for DR were fatigue and anaemia (both 8 patients, 22%). One patient had grade 3 pneumonitis, one had a grade 4 allergic reaction, and one developed a secondary cancer (SCC of tongue) whilst on treatment.

Conclusions DR were more common in all patients and PFS and OS in the recurrent population was shorter in a real world population than in published trial data, but longer than in the placebo arm. Long term responders are seen.

IGCS20_1433

402 TREATMENT PATTERNS POST PARP INHIBITOR IN EPITHELIAL OVARIAN CANCER PATIENTS: RESULTS FROM AN AUSTRALIAN, RETROSPECTIVE, MULTI-INSTITUTE COHORT STUDY

¹T Sivakumaran*, ^{2,3,4}M Krasovitsky, ^{1,5,6}A Freimund, ^{2,3,4,7}K Chen Lee, ⁸K Webber, ⁸J So, ^{2,3}C Norris, ^{2,3,4}M Friedlander, ^{1,5,6,9}L Mileschkin, ^{1,5,6,9}G Au-Yeung. ¹Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; ²Prince of Wales Hospital, Randwick, NSW, Australia; ³Royal Hospital for Women, Randwick, NSW, Australia; ⁴Prince of Wales Clinical School, University of New South Wales, NSW, Australia; ⁵Royal Women's Hospital, Melbourne, VIC, Australia; ⁶Mercy Hospital for Women, Heidelberg, VIC, Australia; ⁷NHMRC Clinical Trials Centre, University of Sydney, NSW, Australia; ⁸Monash Hospital, Clayton, VIC, Australia; ⁹Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia

10.1136/ijgc-2020-IGCS.347

Introduction PARP inhibitors (PARPi) have changed the management landscape for patients with epithelial ovarian cancer (EOC). However, as with many targeted therapies, treatment resistance is common. The response to treatment post-PARPi has not been well described in trials. Data is needed to better understand disease course, and guide treatment decisions. The primary aim is to describe the treatment patterns post-PARPi. Secondary aims are to describe patient characteristics who received chemotherapy post-PARPi and DoR to chemotherapy. **Methods** Retrospective analysis of women with EOC treated with PARPi either in the maintenance or treatment setting and via government-funded or clinical trial access at six gynaecological oncology centres. Between 2007–2019 eligible women were identified via clinics, trial databases and pharmacy dispensing logs. Information regarding clinico-pathological characteristics and treatment outcomes were collated from medical records.

Results Eighty-five women with EOC were identified. 90.6% received chemotherapy post-PARPi, with 72.7% receiving platinum-based chemotherapy. Clinicopathological characteristics in table 1.

Best responses observed were 5.2% CR, 19.5% PR, 19.5% SD, and 55.8% PD. Median DOR was 7.0 months (range, 0.2

Abstract 402 Table 1 Clinicopathological characteristics

	N (%)
BRCA1/2 status	
BRCA1/2 wildtype	25 (29.4)
Germline or somatic BRCA1	43 (50.6)
Germline or somatic BRCA2	17 (20)
Lines of treatment prior to PARPi	
< 2	28 (32.9)
≥ 2	57 (67.1)
Platinum sensitivity prior to PARPi	
Sensitive	76 (89.4)
Resistant	7 (8.2)
Refractory	2 (2.4)
Intent of PARPi	
Treatment	59 (69.4)
Maintenance	26 (30.6)
Chemotherapy post PARPi	
Platinum single agent	16 (18.8)
Platinum doublet	40 (47.1)
Non-platinum chemotherapy	21 (24.7)

– 20.4 months) in 77 patients receiving chemotherapy post-PARPi. Eight patients did not receive further systemic therapy due to poor performance status. Women who received platinum doublet chemotherapy post-PARPi had a longer mPFS than those receiving platinum single agent or non-platinum chemotherapy (9.1 months vs 3.3 months vs 5.0 months, respectively $p=0.0004$).

Conclusion Most patients received-platinum based chemotherapy post-PARPi with a modest response rate. Potential overlapping mechanisms of resistance to PARPi and platinum require further study to improve patient outcomes.

IGCS20_1432

403

TREATMENT PATTERNS POST PARP INHIBITOR IN EPITHELIAL OVARIAN CANCER PATIENTS: RESULTS FROM AN AUSTRALIAN, RETROSPECTIVE, MULTI-INSTITUTE COHORT STUDY

¹T Sivakumaran*, ²M Krasovitsky, ²YC Lee, ²C Norris, ²M Friedlander. ¹Peter MacCallum Cancer Centre, Australia; ²Peter MacCallum Cancer Centre, Royal Women's Hospital and Mercy Hospital for Women, Australia

10.1136/ijgc-2020-IGCS.348

Introduction PARP inhibitors (PARPi) have changed the management landscape for patients with epithelial ovarian cancer (EOC). However, as with many targeted therapies, treatment resistance is common. The response to treatment post-PARPi has not been well described in trials. Data is needed to better understand disease course, and guide treatment decisions. The primary aim is to describe the treatment patterns post-PARPi. Secondary aims are to describe patient characteristics who received chemotherapy post-PARPi and DoR to chemotherapy.

Methods Retrospective analysis of women with EOC treated with PARPi either in the maintenance or treatment setting and via government-funded or clinical trial access at six gynaecological oncology centres. Between 2007–2019 eligible women were identified via clinics, trial databases and pharmacy

dispensing logs. Information regarding clinico-pathological characteristics and treatment outcomes were collated from medical records.

Results Eighty-five women with EOC were identified. 90.6% received chemotherapy post-PARPi, with 72.7% receiving platinum-based chemotherapy. Clinicopathological characteristics in table 1.

Best responses observed were 5.2% CR, 19.5% PR, 19.5% SD, and 55.8% PD. Median DOR was 7.0 months (range, 0.2 – 20.4 months) in 77 patients receiving chemotherapy post-PARPi. Eight patients did not receive further systemic therapy due to poor performance status. Women who received platinum doublet chemotherapy post-PARPi had a longer mPFS than those receiving platinum single agent or non-platinum chemotherapy (9.6 months vs 3.3 months vs 4.6 months, respectively $p=0.51$).

Conclusion Most patients received-platinum based chemotherapy post-PARPi with a modest response rate. Potential overlapping mechanisms of resistance to PARPi and platinum require further study to improve patient outcomes.

IGCS20_1436

404

MESONEPHRIC ADENOCARCINOMA; A CASE REPORT AND REVIEW OF THE LITERATURE

¹M Daas*, ²S Addley, ²H Soleymani Majd, ²E Jackson, ²M Alazzam. ¹Jordan University, Jordan; ²Oxford University Hospitals, UK

10.1136/ijgc-2020-IGCS.349

Introduction Mesonephric cancer is an extremely rare form of neoplasms that arises from the mesonephric duct remnants, the majority of cancers originating from the mesonephric duct are in the cervix, only 67 cases were reported in the literature. We present here the case of a 53-year-old woman who previously had a subtotal hysterectomy and was referred to the colposcopy clinic due to borderline changes in her cervical smear, Punch biopsy reported as suspicious, further loop (LEEP) cervical excision showed at least 1B1 mesonephric carcinoma of the cervix. Preoperative MRI scan showed a 2.2 cm carcinoma cervix but no metastasis or lymphadenopathy. She underwent radical cervical stumpectomy, upper vaginectomy, bilateral salpingo-oophorectomy, and bilateral pelvic nodes dissection. The histology confirmed the diagnosis, there was no spreading in parametria or lymph nodes, however, vaginal margins were involved. She had further adjuvant chemoradiotherapy.

Methods We conducted a systematic literature review for all English published literature from January 1960 until December 2019.

Results 67 cases were reported in the literature. The stage was documented only in 58 cases. 60% of those were clinically described as IB. Surgical treatment varied between simple hysterectomy without lymphadenectomy to radical hysterectomy with pelvic lymphadenectomy. In 50% of those who underwent surgery, the vaginal margins were positive. Recurrence was documented in 45% of the patients.

Conclusions The mesonephric cervical tumour appears to have a more aggressive behaviour with higher rates of vaginal extension and recurrence rates despite multiple treatment modalities. There is a clear need for consensus and guidance into the management of this condition.

Abstract 403 Table 1 Clinicopathological characteristics

	N (%)
BRCA1/2 status	
BRCA1/2 wildtype	25 (29.4)
Germline or somatic BRCA1	43 (50.6)
Germline or somatic BRCA2	17 (20)
Lines of treatment prior to PARPi	
< 2	28 (32.9)
≥ 2	57 (67.1)
Platinum sensitivity prior to PARPi	
Sensitive	76 (89.4)
Resistant	7 (8.2)
Refractory	2 (2.4)
Intent of PARPi	
Treatment	59 (69.4)
Maintenance	26 (30.6)
Chemotherapy post PARPi	
Platinum single agent	16 (18.8)
Platinum doublet	40 (47.1)
Non-platinum chemotherapy	21 (24.7)